Phase II trial of lazertinib in epidermal growth factor receptor (EGFR) mutation-positive (M+), metastatic non-small cell lung cancer (NSCLC) patients with asymptomatic or mild symptomatic brain metastases after failure of EGFR tyrosine kinase inhibitor (TKI) (KCSG LU20-15).

Authors

Min Hee Hong

Yonsei Cancer Center, Seoul, South Korea

Min Hee Hong , Yoon Ji Choi , Hee Kyung Ahn , Bhumsuk Keam , Yu Jung Kim , Ju Won Kim , Hye Ryun Kim , Jin-Hyoung Kang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2021 ASCO Quality Care Symposium

bookmark_border

Real-world treatment patterns of metastatic non-small cell lung cancer (mNSCLC) patients receiving epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs).

First Author: Rahul Shenolikar

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

Activity of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients (pts) with NSCLC with uncommon EGFR mutations: A real-world cohort study (UpSwinG).

First Author: Satoru Miura

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

Outcomes of first-generation versus third-generation epidermal growth factor receptor (EGFR) inhibitors in non-small cell lung cancer with brain metastases (NSCLCBM).

First Author: Vineeth Tatineni

insert_chart_outlined

Poster

2017 ASCO Annual Meeting

bookmark_border

Afatinib (Afa) plus bevacizumab (Bev) combination after acquired resistance (AR) to EGFR-tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small cell lung cancer (NSCLC): Multicenter single arm phase II trial (ABC-study).

First Author: Akito Hata